Cardiovascular Therapeutics最新文献

{"title":"Machine Learning Integrates Bulk and Single-Nucleus RNA Sequence to Explore Apoptosis-Related Gene in Myocardial Infarction","authors":"Bin Li,&nbsp;Yuan Wu,&nbsp;Shude Liao,&nbsp;Jing Wang,&nbsp;Panting Wei,&nbsp;Chenghui Yan,&nbsp;Dali Zhang,&nbsp;Dan Liu,&nbsp;Yaling Han","doi":"10.1155/cdr/5553167","DOIUrl":"10.1155/cdr/5553167","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Myocardial infarction (MI) remains a predominant contributor to global cardiovascular disease death, with apoptosis playing a pivotal yet incompletely characterized role in adverse cardiac remodeling. Despite advances in bulk RNA sequence analyses, the single-cell level analyses of apoptotic signaling of MI progression remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Multiomics data integration was synthesized through single-nucleus RNA-seq (snRNA-seq) (GSE270788) and bulk RNA-seq (GSE21610). Three hundred ninety-seven ARGs (apoptosis-related genes) were downloaded from GeneCards (relevance score &gt; 7), followed by identification of candidate genes through AUCell scoring and correlation analysis. Random Forest, Boruta, and LASSO algorithms were employed to refine hub genes. Hub genes were validated by animal and cell experiments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Single-nucleus sequence analysis reveals dramatic variation in ARGs activity across cardiac cells after MI, with fibroblasts demonstrating significantly elevated apoptotic activity compared with other cell types. Integration of single-nucleus and bulk sequence confirms TNFRSF12A as the major molecule regulating ARGs activation in MI. Experiment validation confirmed that upregulation of TNFRSF12A in the MI model and TGF-<i>β</i> induced NIH3T3.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study revealed that fibroblast dominates apoptotic activity post-MI. We identified TNFRSF12A as a key regulator in MI through multiomics analysis, with potential as a diagnostic biomarker and therapeutic target.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/5553167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asprosin Protects H9C2 Cells From Ferroptosis Following Hypoxia/Reoxygenation by Promoting Mitophagy","authors":"Xiangkun Wang,&nbsp;Xiaoyu Zhang,&nbsp;Huaiguang Tang,&nbsp;Xiaojuan Su,&nbsp;Shutong Ding,&nbsp;Xuelian Li,&nbsp;Bingong Li","doi":"10.1155/cdr/8401037","DOIUrl":"https://doi.org/10.1155/cdr/8401037","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute myocardial infarction is a leading cause of death globally. Percutaneous coronary intervention is the primary treatment to restore blood flow to the affected myocardium, but reperfusion can cause myocardial injury, affecting the prognosis of patients with acute myocardial infarction. Asprosin (ASP) is a newly discovered adipokine whose role in myocardial protection requires further research.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The GSE240847 dataset was downloaded from the GEO database, and 511 ferroptosis-related genes were collected from the FerrDb database. Gene coexpression network analysis (WGCNA) was performed to identify coexpression modules associated with Fibrillin 1 (FBN1), followed by enrichment analysis. H9C2 cells were subjected to hypoxia/reoxygenation (H/R) and pretreated with ASP at different concentrations. The effects of ASP were determined by measuring cellular reactive oxygen species (ROS), Cell Counting Kit-8 (CCK-8), and lactate dehydrogenase (LDH) levels and assessing the expression of ferroptosis-related proteins, intracellular iron content, mitophagy-related proteins, and mitochondrial membrane potential.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Enrichment analysis showed Gene Ontology (GO) terms linked to GTPase signaling, chromosome behavior, and cell stability. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis highlighted mitophagy and MAPK pathways in the FBN1 module. ASP cut ROS, boosted cell viability, and raised glutathione peroxidase 4 (GPX4)/solute carrier family 7 member 11 (SLC7A11) expression, upregulating glutathione and lowering iron particles dose dependently post H/R. It also increased PINK1 and stabilized mitochondria. A mitophagy inhibitor reduced these effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study confirms the protective effects of ASP on myocardial cells after H/R injury and demonstrates that ASP can inhibit ferroptosis and promote mitophagy in myocardial cells during ischemia–reperfusion injury. The potential mechanism may involve ASP promoting PINK1-associated mitophagy in myocardial cells after H/R injury to inhibit ferroptosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/8401037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147564647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretable Machine Learning Model for Predicting 30-Day Readmission in Advanced Heart Failure Patients: Synergistic Assessment of Inflammatory and Metabolic Biomarkers","authors":"Baohe Zang,&nbsp;Chengyu Li,&nbsp;Min Zhou,&nbsp;Yali Chao","doi":"10.1155/cdr/2307901","DOIUrl":"https://doi.org/10.1155/cdr/2307901","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with advanced heart failure (AdHF) face a high risk of early readmission, leading to poor outcomes and increased healthcare burden. Early identification of high-risk individuals remains a clinical challenge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 769 AdHF patients from the Affiliated Hospital of Xuzhou Medical University, with an independent external validation performed on a cohort of 495 AdHF patients from Shanghai Tenth People′s Hospital. After handling missing data via multiple imputation, the dataset was randomly split into training and validation sets in a 7:3 ratio. Class imbalance was addressed by applying the synthetic minority oversampling technique (SMOTE) exclusively within the training set, followed by the least absolute shrinkage and selection operator (LASSO)-based feature selection. Seven machine learning models were developed. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curve, accuracy, sensitivity, specificity, F1 score, and Brier score, among others. SHAP values and a web-based dynamic nomogram were used for model interpretation and clinical application.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The 30-day readmission rate was 30.9%. RF achieved the highest AUC (0.85), accuracy (0.79), and the lowest Brier score (0.159). Key predictors included C-reactive protein (CRP), triglyceride-glucose-body mass index (TYG-BMI), neutrophil-to-lymphocyte ratio (NLR), age, New York Heart Association (NYHA) class, atrial fibrillation (AF), comorbidity count, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (ACEI/ARB/ARNI) use. SHAP analysis confirmed the importance of inflammatory and metabolic markers. A web-based nomogram was constructed to allow interactive risk prediction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study presents a robust and interpretable model for predicting a 30-day readmission in AdHF patients, highlighting the role of inflammation, metabolism, and comorbidity burden. The model can assist clinicians in risk stratification and personalized postdischarge management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/2307901","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147564216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vasoactive–Inotropic Score Reduction Rate Is Highly Associated With Prognosis for Critically Ill Patients With Cardiogenic Shock: Insights From the Real-World Dynamic Data","authors":"Yi-Le Ning,&nbsp;Tian-Xiang Guan,&nbsp;Xiao-Li Niu,&nbsp;Qian-Qian Ma,&nbsp;Yuan-Na Zhang,&nbsp;Ting-Yu Peng,&nbsp;Li-Xiong Zeng,&nbsp;Hang Li,&nbsp;Hui-Ting Guan","doi":"10.1155/cdr/8989505","DOIUrl":"10.1155/cdr/8989505","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In cardiogenic shock (CS), titration of both the choice and dosage of inotropes and vasopressors is crucial. The vasoactive–inotropic score (VIS) quantifies hemodynamic support, while the effect of temporal VIS change on prognosis remains unclear. This study evaluated the association between the vasoactive–inotropic score reduction rate (VRR) to measure VIS changes over time and explore its association with mortality in CS patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a retrospective observational study using two large intensive care databases (MIMIC-IV and eICU). Adult patients with CS receiving vasoactive–inotropic agents within 24 h after ICU admission were included. VIS was calculated using the updated VIS 2020, and VRR was defined to capture the relative change in VIS over time. Patients were categorized into VIS-decreasing and VIS-increasing groups. The primary outcome was in-hospital mortality; secondary outcomes were intensive care unit (ICU) and 28-day mortality (28-day mortality only for the MIMIC-IV database). Associations between VRR and outcomes were examined using four models: (1) log-rank analysis, (2) Cox model adjusted for all covariates, (3) Cox model adjusted for covariates selected by univariable analyses, and (4) Cox model adjusted for covariates selected by a random forest algorithm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 3170 adult CS patients were analyzed. All models in both MIMIC-IV and eICU showed that an increasing VIS over time was consistently associated with higher in-hospital, ICU, and 28-day mortality compared with a decreasing VIS in the MIMIC-IV cohort (<i>p</i> &lt; 0.001). These findings were reproduced in the external eICU cohort for ICU and in-hospital mortality (<i>p</i> &lt; 0.001), supporting the robustness and generalizability of VRR as a prognostic indicator across heterogeneous ICUs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In adult CS patients, a greater reduction in VIS over time is strongly associated with lower mortality. VRR provides a simple, dynamic summary of vasoactive trajectories and may serve as a useful adjunct for risk stratification alongside other clinical and biochemical markers, although prospective validation is warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of the Metal Mixture Inflammation Index on All-Cause Mortality in Patients With Cardiovascular-Kidney-Metabolic Syndrome Stages 0–3: A Study Based on NHANES 1999–2010","authors":"Wenlong Ding,&nbsp;Fachao Shi,&nbsp;Lei Fang,&nbsp;Qin Cui,&nbsp;Caoyang Fang","doi":"10.1155/cdr/1178167","DOIUrl":"10.1155/cdr/1178167","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Environmental exposure to metals is recognized as a significant trigger of chronic inflammation and various systemic diseases, with inflammatory processes playing a central role in the development and progression of CKM syndrome. The MMII, which integrates multiple metal exposures and inflammatory responses, has demonstrated sensitivity in predicting population health risks. However, its association with all-cause mortality in individuals with CKM Stages 0–3 has not been previously investigated.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study analyzed publicly available data from the NHANES 1999–2010, including adults aged 20 years and older with CKM syndrome Stages 0–3. The MMII was constructed based on urinary concentrations of heavy metals (mercury, cadmium, cobalt, molybdenum, lead, and tungsten) along with C-reactive protein and white blood cell count. The primary outcome was all-cause mortality. Cox proportional hazards regression models were employed to assess the association between MMII and all-cause mortality, with sequential adjustment for potential confounders, complemented by sensitivity and subgroup analyses.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The final analysis included 2643 participants (mean age: 44.24 years; 56.77% female). Higher MMII levels were significantly associated with increased all-cause mortality. In the fully adjusted model, participants in the highest MMII quartile exhibited a hazard ratio (HR) for all-cause mortality of 1.50 (95% CI: 1.01–2.22, &lt;i&gt;p&lt;/i&gt; = 0.04). Restricted cubic spline analysis revealed a nonlinear dose–response relationship between MMII and mortality risk (P for nonlinearity = 0.007). Threshold effect analysis identified an inflection point at MMII = 0.10594.&lt;/p&gt;\u0000 \u0000 &lt;p&gt;Threshold effect analysis identified an inflection point at MMII = 0.10594. Below this threshold, the association between MMII and all-cause mortality was not statistically significant, with a point estimate below 1 and wide confidence intervals (HR: 0.554, 95% CI: 0.171–1.795). Above the threshold, higher MMII was associated with greater mortality risk (HR: 3.977, 95% CI: 1.777–8.901). Sensitivity analyses yielded consistent results. Subgroup analysis revealed a significant interaction between MMII and age group for mortality risk (&lt;i&gt;p&lt;/i&gt; &lt; 0.05).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In the U.S. population with CKM Stages 0–3, MMII is significantly associated with all-cause mortality. These findings highlight the importance of the inflammatory ","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12948730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Atrial Fibrillation Impacted by Completeness of Coronary Revascularization and Antiplatelet Regimen","authors":"Qin Jiang,&nbsp;Minghui Xie,&nbsp;Yalu Yu,&nbsp;Zhiai Tang,&nbsp;Jiaqi Xia,&nbsp;Shengshou Hu","doi":"10.1155/cdr/8857148","DOIUrl":"10.1155/cdr/8857148","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Postoperative atrial fibrillation (POAF) is a common complication after off-pump coronary artery bypass grafting (OPCABG) and contributes to increased morbidity and prolonged hospital stays. Both myocardial ischemia and systemic inflammation play a critical role in its pathogenesis, which is closely related to the intensity of coronary revascularization and antiplatelet treatment, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study investigated the impact of the interaction between completeness of coronary revascularization and antiplatelet regimen on POAF incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 505 eligible patients, undergoing elective first-time OPCABG surgery from May 2017 to May 2024, were reviewed and divided into the incomplete revascularization (IR) group (<i>n</i> = 143) and complete revascularization (CR) group (<i>n</i> = 362) according to the extent of coronary revascularization. The incidence of POAF within the first week post-OPCABG was 39.2% in the IR group versus 25.1% in the CR group (hazard ratio [HR]: 1.70, 95% confidence interval [CI]: 1.18–2.46; <i>p</i> = 0.002). AF burden (10.1% [IQR 4.8%, 16.5%] vs. 6.0% [IQR 2.3%, 9.5%], <i>p</i> = 0.003), inflammatory markers (interleukin-6 [IL-6] on Day 1: 104 ± 20 vs. 98 ± 16 pg/mL, <i>p</i> &lt; 0.001), markers of prothrombotic state (D-dimer on Day 5: 2.6 ± 0.7 mg/L FEU vs. 2.3 ± 0.7 mg/L FEU, <i>p</i> &lt; 0.001), and postoperative hospital stay (10.7 ± 1.8 vs. 10.3 ± 1.8 days, <i>p</i> = 0.006) were significantly higher in the IR group compared to the CR group. Among patients receiving clopidogrel, POAF incidence was 42.6% (IR) vs. 25.9% (CR) (<i>p</i> = 0.001). Among patients receiving ticagrelor, POAF incidence was 25.0% (IR) vs. 22.5% (CR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>IR was associated with a higher rate of POAF after OPCABG in patients receiving clopidogrel-based DAPT, but not in those receiving ticagrelor-based DAPT.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12945922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Combined Double-Orifice and Single-Patch Technique for Partial Atrioventricular Septal Defect in Adults: A Novel Strategy","authors":"Hua-Jie Zheng,&nbsp;Rui-Han Xiao,&nbsp;Mao-Ting Ye,&nbsp;Jun Li,&nbsp;Mei Guo,&nbsp;San-Jiu Yu,&nbsp;Yong-Bo Cheng,&nbsp;Wei Cheng","doi":"10.1155/cdr/8493694","DOIUrl":"10.1155/cdr/8493694","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The aim of this study is to share our experience of the combined double-orifice and single-patch technique for the correction of partial atrioventricular septal defect (pAVSD) and its associated tricuspid valve dysplasia (TVD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Between January 2014 and May 2024, 99 patients (age ≥ 18 years) who underwent repair of pAVSD and its associated TVD using the aforementioned strategy were retrospectively analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean aortic cross-clamp time was 48.5 ± 12.6 min, and the mean cardiopulmonary bypass time was 75.8 ± 13.0 min. Follow-up was 100% at a mean of 5.2 years (3–8 years). No operative or late deaths occurred. No evidence of mitral stenosis was detected, and only one patient developed a severe MR 2 years after the surgery and underwent reoperation. There was no moderate or severe tricuspid regurgitation during follow-up. There was neither secondary tricuspid valve repair nor permanent pacemaker implantation among all patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The combined double-orifice and single-patch technique is a safe, effective, and durable strategy for repair of pAVSD and its associated TVD, demonstrating an excellent technical reproducibility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12932322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147302599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases”","authors":"","doi":"10.1155/cdr/9764793","DOIUrl":"10.1155/cdr/9764793","url":null,"abstract":"<p>W. Li, D. Wang, C. Lin, et al., “A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases,” <i>Cardiovascular Therapeutics</i> 2025, no. 1 (2025): 1–29, https://doi.org/10.1155/cdr/6684099.</p><p>In the article titled “A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases,” incorrect funding details were included.</p><p>The correct funding statement should read:</p><p>This work was funded by the Fifth Batch of National Outstanding Traditional Chinese Medicine Clinical Talent Cultivation Program (National Administration of Traditional Chinese Medicine, Document No. [2022] 239) and the Guangxi First-Class Discipline Construction Project (Gui Jiao Ke Yan [2022] No. 1).</p><p>We apologize for this error.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12931147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147302647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study","authors":"Jie Wang,&nbsp;Shanshan Qi,&nbsp;Siyuan Chen,&nbsp;Hang Yu","doi":"10.1155/cdr/5113761","DOIUrl":"10.1155/cdr/5113761","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dilated cardiomyopathy (DCM) is characterized by left ventricular dilation and systolic dysfunction in the absence of severe hypertension, valvular disease, or coronary artery disease. Patients with DCM have a high risk of atrial fibrillation (AF), especially when combined with Type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown cardioprotective effects in patients with diabetes, suggesting potential benefits in reducing AF incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed clinical data from patients with T2DM diagnosed with DCM treated at the First Affiliated Hospital of Xi’an Jiaotong University between January 2018 and January 2024. Patients were divided into two groups based on their use of SGLT2i. The incidence of AF was compared between these groups using logistic regression models adjusted for potential confounders, including demographic characteristics, comorbidities, and medication history. Additionally, a subgroup analysis was conducted to evaluate the relationship between AF and SGLT2i.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 455 enrolled patients, 95 (20.9%) were treated with SGLT2i. The incidence of AF was significantly lower in the SGLT2i group compared with the control group (7/95 [7.4%] vs. 68/360 [18.9%]; OR = 0.308, 95<i>%</i>CI = 0.132–0.735, <i>p</i> = 0.008). Subgroup analyses showed consistent results across various age, gender, hypertension status, and diabetes duration groups, indicating the robustness of the association between SGLT2i use and reduced AF incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study suggests that SGLT2i use is associated with a lower incidence of AF in patients with T2DM and DCM. This observed association warrants further investigation in prospective studies to elucidate its nature.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12907262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxycodone: A Pain-Relieving Agent With Cardioprotective Properties Against Myocardial Ischemia–Reperfusion Injury","authors":"Mehdi Dehghani Firoozabadi,&nbsp;Behrang Nooralishahi,&nbsp;Fatemeh Rezaei-Tazangi","doi":"10.1155/cdr/6182342","DOIUrl":"10.1155/cdr/6182342","url":null,"abstract":"<p>In the realm of cardiovascular diseases, myocardial ischemia–reperfusion injury (MIRI) is known as one of the main life-threatening conditions with significant morbidity and mortality. Although some therapeutic approaches, like pharmacological treatments and ischemic preconditioning, have been suggested for MIRI, offering a functional approach with high effectiveness for MIRI remains challenging. Recent studies have indicated that oxycodone, a semisynthetic opioid used to improve acute to chronic pain, may be cardioprotective against MIRI. The current experimental evidence showed that these protective influences can stem from the ability of oxycodone to regulate apoptosis, inflammation, and oxidative stress, as well as promote cardiovascular parameters (e.g., infarct size, cardiac function, and endothelial integrity). Hence, the main purpose of this narrative review study is to summarize and discuss the anti-MIRI potential of oxycodone with a mechanistic insight. This narrative review was also conducted to hold promise for researchers and clinicians to consider and assess its clinical capacity for subjects suffering from this challenging disease.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12903989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}